Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Commercial Services & Supplies
Near term
6-12 MONTHS
With the North American execution seemingly enjoying improved demand and operating leverage, eyes now turn to Other Markets, where BTS has guided for a return to profitable growth in H2 2026. Following the weak performance in 2025, BTS focus on restoring EBITA per FTE yields over the past 6-12 months have now started to yield results we believe. As such, we believe BTS could be entering a harvest period in the coming quarters, following a period of implemented cost-savings initiatives, particularly in the US.
Long term
6+ YEARS
Over the long term, we believe BTS should be able to continue its impressive growth journey. With wide geographical and end-market exposure, we believe BTS is well positioned. Furthermore, we expect BTS to continue pursuing the occasional acquisition, as it has done in its past, either buying technology or building a stronger market presence. In terms of profitability, BTS targets a long-term EBITA margin of 17%; we believe it can achieve this through: 1) increasing utilisation; 2) significantly cutting FTEs primarily working in the back end; and 3) increasing the proportion of revenue from SaaS and licences.
Adverse effects on BTS North America operations from Trump administration policies.
Loss of key personnel.
Overpaying or failure to integrate acquisitions could have an adverse impact on BTS’s financial profile.
Price
Fair range high value
Fair range low value
BTS’ Nordic and international peers are currently trading at combined average 10x EBITA 2027e, which we apply to derive the lower end of our valuation range. Its three-year average EV/EBIT is 14x, which we apply to yield the upper end of the range.
Our fair-value range reflects a 2027e EV/EBITA of 10–14x, where we adjust reported EBITA for amortisation of capitalised R&D investments.
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB